A groundbreaking study has unveiled a new triple therapy combining inavolisib, palbociclib, and fulvestrant for aggressive, advanced breast cancer. This treatment has been shown to improve overall survival rates by an average of seven months, while it also significantly delayed disease progression, with an average of 17.2 months compared to just 7.3 months in the control group. Notably, patients receiving this therapy postponed the need for subsequent chemotherapy by almost two years. Presented at the ASCO annual meeting, the results mark a significant advancement in targeted treatments for PIK3CA-mutated HR+, HER2- breast cancer.
The trial findings indicate that the triple therapy not only slows cancer progression but significantly enhances overall survival rates for patients.
The combination of inavolisib, palbociclib, and fulvestrant has been shown to extend the time before chemotherapy is needed by nearly two years.
Collection
[
|
...
]